Novo Nordisk, BioNxt Solutions, Evotec – when injections become tablets, the cash register rings

{
  "signal_id": "ceec5f7b-161f-be15-c29e-70558297f112",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-09-21T03:30:00+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.kapitalerhoehungen.de/kommentare/novo-nordisk-bionxt-solutions-evotec-wenn-aus-spritzen-tabletten-werden-klingelt-die-kasse",
    "title": "Novo Nordisk, BioNxt Solutions, Evotec – when injections become tablets, the cash register rings - Kapitalerhöhungen.de",
    "excerpt": "21.09.2026 | 05:30 The daily injection has seen its best days. Swallowing biologics as a tablet was long considered a utopia, but since this year, it has become a multi-billion dollar business. On September 17, 2026, Novo Nordisk announced a partnership with Orbis Medicines worth up to 1.4 billion USD to make injections orally available. In February, the Danes secured a partnership with Vivtex worth up to 2.1 billion USD. Whoever can get peptides through the stomach could have the industry knocking down their door. We therefore look at Novo Nordisk, BioNxt Solutions, and Evotec, which cover the trend from acquisition to technology and development. Reading time: approx. 4 min. | Author: Armin Schulz ISIN: NOVO NORDISK A/S | DK0062498333 , Bionxt Solutions Inc. | CA0909741062 | CSE:BNXT , OTCQB: BNXTF , EVOTEC SE INH O.N. | DE0005664809 Get exciting comments directly as an email newsletter. Subscribe now for free The Author The Mönchengladbach native studied business administration in the Netherlands. During his studies, he first came into contact with the stock market. He has more than 25 years of experience in stock market transactions. More about the authorFor years, injections have been the standard for weight loss medications. But the market is changing rapidly. The Wegovy tablet, approved this year, brought in around 500 million USD for the Danes in the 2nd quarter, making...",
    "summary": "Novo Nordisk is joining Orbis Medicines as an investor as part of a research alliance.",
    "planning": true,
    "image_url": "https://www.kapitalerhoehungen.de/media/pages/kommentare/novo-nordisk-bionxt-solutions-evotec-wenn-aus-spritzen-tabletten-werden-klingelt-die-kasse/c422d02274-1789813226/bionxt-solutions.jpg",
    "confidence": 0.8,
    "published_at": "2026-09-21T03:30:00Z",
    "article_sentence": "Novo is also joining as an investor, paying upfront and milestone payments, plus tiered royalties.",
    "financing_type_tags": [
      "equity"
    ],
    "related_company_name": "Orbis Medicines",
    "related_company_domain": "orbismedicines.com"
  }
}

curl https://signals.autobound.ai/v1/signals/ceec5f7b-161f-be15-c29e-70558297f112 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novonordisk.com","limit":20}'